Nuveen Asset Management, LLC Blueprint Medicines Corp Transaction History

Nuveen Asset Management, LLC

$334 Billion
Q2 2024

A detailed history of Nuveen Asset Management, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 339,493 shares of BPMC stock, worth $31.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

339,493

Previous 266,347 27.46%

Holding current value

$31.4 Million

Previous $25.3 Million 44.82%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$85.18 - $108.78 $6.23 Million - $7.96 Million	73,146 Added 27.46%	339,493 $36.6 Million
Q1 2024 May 13, 2024	SELL	$73.17 - $99.79 $30,072 - $41,013	-411 Reduced 0.15%	266,347 $25.3 Million
Q4 2023 Feb 14, 2024	BUY	$43.96 - $92.84 $3.98 Million - $8.4 Million	90,496 Added 51.34%	266,758 $24.6 Million
Q3 2023 Nov 14, 2023	BUY	$46.9 - $66.0 $90,751 - $127,710	1,935 Added 1.11%	176,262 $8.85 Million
Q2 2023 Aug 14, 2023	SELL	$42.2 - $66.37 $237,290 - $373,198	-5,623 Reduced 3.12%	174,327 $11 Million
Q1 2023 May 15, 2023	SELL	$37.97 - $50.0 $556,146 - $732,350	-14,647 Reduced 7.53%	179,950 $8.1 Million
Q4 2022 Feb 14, 2023	SELL	$41.06 - $66.48 $287,173 - $464,961	-6,994 Reduced 3.47%	194,597 $8.53 Million
Q3 2022 Nov 14, 2022	SELL	$49.93 - $77.7 $2.12 Million - $3.29 Million	-42,402 Reduced 17.38%	201,591 $13.3 Million
Q2 2022 Aug 15, 2022	BUY	$45.23 - $70.15 $652,940 - $1.01 Million	14,436 Added 6.29%	243,993 $12.3 Million
Q1 2022 May 16, 2022	SELL	$54.1 - $110.08 $7.35 Million - $15 Million	-135,898 Reduced 37.19%	229,557 $14.6 Million
Q4 2021 Feb 14, 2022	BUY	$94.25 - $115.99 $446,462 - $549,444	4,737 Added 1.31%	365,455 $39.1 Million
Q3 2021 Nov 12, 2021	BUY	$80.98 - $109.47 $505,963 - $683,968	6,248 Added 1.76%	360,718 $37.1 Million
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $7.13 Million - $8.7 Million	86,132 Added 32.1%	354,470 $31.2 Million
Q1 2021 May 17, 2021	SELL	$90.71 - $108.28 $716,971 - $855,845	-7,904 Reduced 2.86%	268,338 $26.1 Million
Q4 2020 May 17, 2021	BUY	$92.08 - $124.48 $2.12 Million - $2.87 Million	23,061 Added 9.11%	276,242 $31 Million
Q4 2020 Feb 16, 2021	SELL	$92.08 - $124.48 $3.06 Million - $4.14 Million	-33,270 Reduced 11.61%	253,181 $28.4 Million
Q3 2020 Nov 16, 2020	SELL	$66.45 - $92.7 $6.55 Million - $9.14 Million	-98,558 Reduced 25.6%	286,451 $26.6 Million
Q2 2020 Aug 14, 2020	SELL	$57.09 - $79.27 $1.77 Million - $2.45 Million	-30,926 Reduced 7.44%	385,009 $30 Million
Q1 2020 May 14, 2020	BUY	$48.11 - $82.22 $8.28 Million - $14.1 Million	172,088 Added 70.57%	415,935 $24.3 Million
Q4 2019 Feb 14, 2020	BUY	$66.73 - $82.59 $978,328 - $1.21 Million	14,661 Added 6.4%	243,847 $19.5 Million
Q3 2019 Nov 14, 2019	BUY	$72.9 - $101.41 $348,316 - $484,536	4,778 Added 2.13%	229,186 $16.8 Million
Q2 2019 Aug 15, 2019	BUY	$73.54 - $97.8 $15.7 Million - $20.8 Million	212,940 Added 1856.82%	224,408 $21.2 Million
Q1 2019 May 14, 2019	BUY	$48.7 - $86.6 $558,491 - $993,128	11,468 New	11,468 $918,000
Q3 2018 Nov 13, 2018	SELL	$58.91 - $78.32 $1.32 Million - $1.75 Million	-22,389 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $693,602 - $1.15 Million	11,378 Added 103.33%	22,389 $1.42 Million
Q1 2018 May 14, 2018	SELL	$73.28 - $102.95 $396,078 - $556,444	-5,405 Reduced 32.93%	11,011 $1.01 Million
Q4 2017 Feb 14, 2018	SELL	$62.91 - $88.32 $138,150 - $193,950	-2,196 Reduced 11.8%	16,416 $0
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $788,590 - $1.3 Million	18,612	18,612 $1.3 Million

Others Institutions Holding BPMC

# of Institutions

340

Shares Held

62M

Call Options Held

987K

Put Options Held

578K

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.52B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Blueprint Medicines Corp Transaction History